Randomized, double-blind, phase 3 trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-Cell lymphoma

Michael Crump, Sirpa Leppä, Luis Fayad, Je Jung Lee, Alice Di Rocco, Michinori Ogura, Hans Hagberg, Frederick Schnell, Robert Rifkin, Andreas MacKensen, Fritz Offner, Lauren Pinter-Brown, Sonali Smith, Kensei Tobinai, Su Peng Yeh, Eric D. Hsi, Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don ThorntonBoris Lin, Brad Kahl, Norbert Schmitz, Kerry J. Savage, Thomas Habermann

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, double-blind, phase 3 trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-Cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences